Cost-effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for Patients With Heart Failure and Preserved Ejection Fraction—Living on the Edge

Cost-effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction

(2023) Laura P. Cohen et al.   JAMA Cardiology

Heart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association

(2022) Connie W. Tsao et al.   CIRCULATION

The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial

(2022) John A. Spertus et al.   NATURE MEDICINE

SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials

(2022) Muthiah Vaduganathan et al.   LANCET

Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

(2022) Scott D. Solomon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials

(2022) Colin Baigent et al.   LANCET

Cost-effectiveness of Empagliflozin in Patients With Heart Failure With Preserved Ejection Fraction

(2022) Jimmy Zheng et al.   JAMA Internal Medicine

Empagliflozin in Heart Failure with a Preserved Ejection Fraction

(2021) Stefan D. Anker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cost-effectiveness of Dapagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction

(2021) Justin T. Parizo et al.   JAMA Cardiology

Cost-effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection Fraction

(2021) Nicolas Isaza et al.   JAMA Network Open

The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial

(2021) Michael E. Nassif et al.   NATURE MEDICINE

Changes in List Prices, Net Prices, and Discounts for Branded Drugs in the US, 2007-2018

(2020) Inmaculada Hernandez et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

ACC/AHA Statement on Cost/Value Methodology in Clinical Practice Guidelines and Performance Measures

(2014) Jeffrey L. Anderson et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY